Insider Selling: Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Sells 1,000 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) VP Patrick Lamy sold 1,000 shares of the company’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $29.13, for a total transaction of $29,130.00. Following the completion of the transaction, the vice president now directly owns 34,258 shares in the company, valued at approximately $997,935.54. The trade was a 2.84 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

Patrick Lamy also recently made the following trade(s):

• On Tuesday, December 10th, Patrick Lamy sold 925 shares of Akero Therapeutics stock. The stock was sold at an average price of $30.79, for a total value of $28,480.75.

Akero Therapeutics Stock Up 3.3 %

Shares of NASDAQ AKRO opened at $29.34 on Friday. The stock has a market capitalization of $2.05 billion, a P/E ratio of -7.82 and a beta of -0.23. Akero Therapeutics, Inc. has a one year low of $15.32 and a one year high of $37.00. The firm’s 50 day simple moving average is $30.89 and its two-hundred day simple moving average is $27.44. The company has a debt-to-equity ratio of 0.05, a current ratio of 17.25 and a quick ratio of 17.25.

Akero Therapeutics (NASDAQ:AKRO) last released its earnings results on Friday, November 8th. The company reported ($1.05) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.15). As a group, analysts expect that Akero Therapeutics, Inc. will post -3.96 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Simplify Asset Management Inc. boosted its holdings in Akero Therapeutics by 15.6% during the 3rd quarter. Simplify Asset Management Inc. now owns 283,766 shares of the company’s stock valued at $8,141,000 after acquiring an additional 38,279 shares during the period. Perceptive Advisors LLC boosted its stake in shares of Akero Therapeutics by 8.1% during the second quarter. Perceptive Advisors LLC now owns 1,499,897 shares of the company’s stock valued at $35,188,000 after purchasing an additional 112,426 shares during the period. FMR LLC grew its holdings in shares of Akero Therapeutics by 732.1% in the third quarter. FMR LLC now owns 30,337 shares of the company’s stock worth $870,000 after purchasing an additional 26,691 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Akero Therapeutics by 32.8% in the second quarter. Bank of New York Mellon Corp now owns 251,234 shares of the company’s stock worth $5,894,000 after buying an additional 61,988 shares during the period. Finally, Propel Bio Management LLC increased its stake in shares of Akero Therapeutics by 4.9% in the third quarter. Propel Bio Management LLC now owns 343,729 shares of the company’s stock worth $9,862,000 after buying an additional 15,977 shares during the period.

Wall Street Analyst Weigh In

Several research analysts have recently commented on AKRO shares. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of Akero Therapeutics in a report on Monday, November 18th. Citigroup assumed coverage on shares of Akero Therapeutics in a report on Monday, November 18th. They issued a “buy” rating and a $65.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $46.83.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.